Challenges With a Precision Medicine-Based Approach in Oncology

Video

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine